Lecturing advanced immunology to MSc Oncology and MSc Cancer Immunology & Biotechnology students.
The group lead by Dr Andrew Jackson and Professor Poulam Patel, comprises post-doctoral and clinical fellows, several PhD students, and a research technician and is supported by the MRC, industry… read more
The group lead by Dr Andrew Jackson and Professor Poulam Patel, comprises post-doctoral and clinical fellows, several PhD students, and a research technician and is supported by the MRC, industry (X-BioCell Ltd.), Breast Cancer Campaign, Matt's Fund for Cancer Research, and the University of Nottingham. Our research focuses on understanding the molecular pathways through which tumours suppress the immune system with a view to first-in-man immunotherapies.
Our recent focus has concerned targeting specific intracellular signaling pathways in dendritic cells (DC) to modify their function or restore immuno-suppression resulting from malignancy. Key areas of interest include ATM-kinase, p38-MAPK, MEK-ERK and the Unfolded Protein Response pathway (UPR). We have shown that modulation of these pathways impacts on the generation of CD4-responses and this work is now in a pre-clinical phase. The importance of circulating DC including CD1c+ myeloid and SlanDC (collaboration with Dr. Marc Schmitz, Dresden) in advanced cancer patients is a major focus.
Other research (collaboration with Prof Uwe Aickelin) concerns computational simulation of the balance of peripheral iTreg and Th17 responses in healthy immune aging (immunosenescence). This important programme will allow us to understand the immune-status of patients with a view to optimising their immunotherapy.
BCG-Immunotherapy of bladder cancer
Anti-TNF strategies for rheumatoid arthritis
Developing new first-in-man immunotherapies for cancer based on ex vivo DC vaccines, incorporating specific inhibitors of intracellular signalling pathways.